Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

被引：307

作者：

Moriyama, B. ^{[1
]}

Obeng, A. Owusu ^{[2
,3
,4
]}

Barbarino, J. ^{[5
]}

Penzak, S. R. ^{[6
]}

Henning, S. A. ^{[1
]}

Scott, S. A. ^{[2
,7
]}

Agundez, J. A. G. ^{[8
]}

Wingard, J. R. ^{[9
]}

McLeod, H. L. ^{[10
]}

Klein, T. E. ^{[5
]}

Cross, S. J. ^{[11
,12
]}

Caudle, K. E. ^{[11
]}

Walsh, T. J. ^{[13
,14
,15
]}

机构：

[1] NIH, Ctr Clin, Dept Pharm, Bethesda, MD 20892 USA

[2] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA

[3] Mt Sinai Hosp, Dept Pharm, New York, NY 10029 USA

[4] Icahn Sch Med Mt Sinai, Dept Med, Div Gen Internal Med, New York, NY 10029 USA

[5] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[6] Univ North Texas, Dept Pharmacotherapy, Syst Coll Pharm, Ft Worth, TX USA

[7] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA

[8] Univ Extremadura, Dept Pharmacol, Caceres, Spain

[9] Univ Florida, Coll Med, Gainesville, FL USA

[10] H Lee Moffitt Canc Ctr & Res Inst, DeBartolo Family Personalized Med Inst, Div Populat Sci, Tampa, FL USA

[11] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

[12] Univ Tennessee, Coll Pharm, Dept Clin Pharm, Memphis, TN USA

[13] Cornell Univ, Weill Cornell Med Ctr, Transplantat Oncol Infect Dis Program, Dept Med, New York, NY 10021 USA

[14] Cornell Univ, Weill Cornell Med Ctr, Transplantat Oncol Infect Dis Program, Dept Pediat, New York, NY 10021 USA

[15] Cornell Univ, Weill Cornell Med Ctr, Transplantat Oncol Infect Dis Program, Dept Microbiol & Infect Dis, New York, NY 10021 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 01期

基金：

美国国家卫生研究院;

关键词：

INFECTIOUS-DISEASES SOCIETY; INTRAVENOUS VORICONAZOLE; PLASMA-CONCENTRATIONS; 2016; UPDATE; SAFETY; PHARMACOKINETICS; GENOTYPE; EFFICACY; VARIANT; POLYMORPHISMS;

D O I：

10.1002/cpt.583

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).

引用

页码：45 / 51

页数：7

共 50 条

[21] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants
Bousman, Chad A.
Stevenson, James M.
Ramsey, Laura B.
Sangkuhl, Katrin
Hicks, J. Kevin
Strawn, Jeffrey R.
Singh, Ajeet B.
Ruano, Gualberto
Mueller, Daniel J.
Tsermpini, Evangelia Eirini
Brown, Jacob T.
Bell, Gillian C.
Leeder, J. Steven
Gaedigk, Andrea
Scott, Stuart A.
Klein, Teri E.
Caudle, Kelly E.
Bishop, Jeffrey R.
PHARMACOGENETICS AND GENOMICS, 2023, 33 (08): : 181 - 183
[22] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
Crews, K. R.
Gaedigk, A.
Dunnenberger, H. M.
Klein, T. E.
Shen, D. D.
Callaghan, J. T.
Kharasch, E. D.
Skaar, T. C.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (02) : 321 - 326
[23] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron
Bell, G. C.
Caudle, K. E.
Whirl-Carrillo, M.
Gordon, R. J.
Hikino, K.
Prows, C. A.
Gaedigk, A.
Agundez, J. A. G.
Sadhasivam, S.
Klein, T. E.
Schwab, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (02) : 213 - 218
[24] Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review
Morris, Sarah A.
Alsaidi, Ashraf T.
Verbyla, Allison
Cruz, Adilen
Macfarlane, Casey
Bauer, Joseph
Patel, Jai N.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) : 1318 - 1328
[25] Clinical importance of the CYP2C19*17 variant allele for voriconazole
Dolton, Michael J.
McLachlan, Andrew J.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (01) : 137 - 138
[26] From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice
Shubbar, Qamar
Alchakee, Aminah
Issa, Khaled Walid
Adi, Abdul Jabbar
Shorbagi, Ali Ibrahim
Saber-Ayad, Maha
FRONTIERS IN PHARMACOLOGY, 2024, 15
[27] The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics
Scherf-Clavel, Maike
Weber, Heike
Unterecker, Stefan
Frantz, Amelie
Eckert, Andreas
Reif, Andreas
Deckert, Juergen
Hahn, Martina
PHARMACOPSYCHIATRY, 2024, 57 (02) : 69 - 77
[28] The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Rosemary, J.
Adithan, C.
CURRENT CLINICAL PHARMACOLOGY, 2007, 2 (01): : 93 - 109
[29] Evaluation of Compliance and Efficacy with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Tacrolimus in Kidney Transplant Recipients.
Nikirk, M.
Chen, J.
Tillman, E.
AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 785 - 786
[30] CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?
Obeng, Aniwaa Owusu
Egelund, Eric F.
Alsultan, Abdullah
Peloquin, Charles A.
Johnson, Julie A.
PHARMACOTHERAPY, 2014, 34 (07): : 703 - 718

← 1 2 3 4 5 →